Back to search results

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Pancreatic Ductal Adenocarcinoma · Refractory Non-Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Shannon Raue) · sr1657@georgetown.edu · 202-784-5097
    Benjamin Weinberg, MD (Sub-investigator)
    Joshua Reuss, MD (Sub-investigator)
    Contact: Principal Investigator (Samir N. Khleif, MD)

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

    Contact: Study coordinator (Oncology Clinical Research Referral Office) · OncologyResearchReferral@hmhn.org · 551-996-1777
    Contact: Principal Investigator (Martin Gutierrez, MD)
Study leads

  • Samir Khleif, MD

    Principal Investigator

    Georgetown University

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)